Welcome to Ramis
Laboratories Pvt. Ltd.(Formerly known as Bondbay)Manufacturer of Pharmaceutical raw materials, Drug Intermediates, & APISRead More
Our range is formulated using high grade raw material as per the requirements of pharma and chemical industries. Quality has been the major factor behind Ramis Laboratories success in the wide competitive arena.
Read More
Ramis Laboratories supplies APIs to many of the major generic drug companies
We are the leading supplier of a broad range of Pharmaceutical Intermediates
Over the years, we have leveraged our position in the global market with an enviable list of clients and a phenomenal growth rate achieved through product innovation, dedicated teams and timely implementation of solutions.
Ramis facilities have integrated quality systems and processes to ensure adherence to cGMP (current Good Manufacturing practices). They are also vertically integrated and can be utilized for large-scale production of APIs.
One of the main duties of Ramis Laboratories and all our employees and business partners is to fulfil the current and future requirements of our customers. To perform this duty, we ensure the highest quality standard for our products.
We produce a comprehensive, diverse and highly complementary portfolio of specialty and generic products targeting a wide spectrum of chronic and acute treatments. Pharmaceutical formulation at Ramis Laboratories is run by a specialized section - New Products – which takes the potential new molecules from the discovery to preclinical development phases by designing the pharmaceutical drug, the right dosage forms and the manufacturing process, with the purpose of securing the absorption of the drug molecule into the human body.
Integrity enhances your drug discovery and development research by integrating essential biological, chemical and pharmacological data to support successful drug research and development.
Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost.
Review the specific challenges manufacturing organizations are facing today and learn about ways to leverage technology to address regulatory needs and economic concerns. Manufacturing, operations, and IT professionals from CMO
First-generation antibody drug conjugates (ADCs) have development challenges including non-uniform and non-optimized drug-to-antibody ratios (DAR). These technologies allow a high degree of control over conjugation site, DAR, and conjugation of cargoes.
Getting children to take their medication is an age-old challenge. It’s not a spoonful of sugar, but effective formulation strategies, that offer the solution. Formulation acceptability has become a key criterion for developing new drugs ensure patient compliance.
